A study published in the European Heart Journal reveals that patients who experienced heart attacks during the initial COVID-19 lockdowns in the UK and Spain are expected to have a significantly reduced life expectancy—by 1.5 years in the UK and 2 years in Spain—compared to those who had heart attacks before the pandemic. This decline in life expectancy is attributed to delayed treatment for ST-elevation myocardial infarction (STEMI) caused by pandemic restrictions. The analysis indicates that the long-term financial repercussions in the UK and Spain will amount to £36.6 million (€41.3 million) and €88.6 million, respectively, primarily driven by productivity losses from work absences. During the lockdown, hospitalization rates for heart attack patients dropped significantly, leading to higher mortality and complications due to delayed treatments. The research underscores the urgent need for resilient healthcare systems that maintain emergency services even during crises. Additionally, public awareness campaigns promoting timely medical care are advocated to mitigate the consequences of delayed treatments. The findings highlight the lasting impact of delayed care on both individual health and broader societal economic burdens.
